Mahidol University Health Technology Assessment Graduate Program, Mahidol University, Bangkok, Thailand; Department of Pharmacy, College of Pharmacy, University of the Philippines Manila, Manila, Philippines.
Mahidol University Health Technology Assessment Graduate Program, Mahidol University, Bangkok, Thailand; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Value Health. 2021 Oct;24(10):1423-1434. doi: 10.1016/j.jval.2021.05.018. Epub 2021 Aug 6.
Although many reviews of the literature on cost-effectiveness thresholds (CETs) exist, the availability of new studies and the absence of a fully comprehensive analysis warrant a new review. This study systematically reviews demand-side methods for estimating the societal monetary value of health gain.
Several electronic databases were searched from inception to October 2019. To be included, a study had to be an original article in any language, with a clearly described method for estimating the societal monetary values of health gain and with all estimated values reported. Estimates were converted to US dollars ($), using purchasing power parity (PPP) exchange rates and the gross domestic product (GDP) per capita (2019).
We included 53 studies; 45 used direct approach and 8 used indirect approach. Median estimates from the direct approach were PPP$ 24 942 (range 554-1 301 912) per quality-adjusted life-year (QALY), which were typically 0.53 (range 0.02-24.08) GDP per capita. Median estimates using the indirect approach were PPP$ 310 051 (range 36 402-7 574 870) per QALY, which accounted for 7.87 (range 0.68-116.95) GDP per capita.
Our review found that the societal values of health gain or CETs were less than GDP per capita. The great variety in methods and estimates suggests that a more standardized and internationally agreed methodology for estimating CET is warranted. Multiple CETs may have a role when QALYs are not equally valued from a societal perspective (eg, QALYs accruing to people near death compared with equivalent QALYs to others).
尽管已有许多关于成本效益阈值(CET)的文献综述,但新研究的出现和缺乏全面分析的情况,使得有必要进行新的综述。本研究系统地回顾了用于估计健康收益的社会货币价值的需求方方法。
从开始到 2019 年 10 月,我们搜索了多个电子数据库。要被包括在内,研究必须是任何语言的原始文章,明确描述了估计健康收益的社会货币价值的方法,并且报告了所有估计值。使用购买力平价(PPP)汇率和人均国内生产总值(2019 年)将估计值转换为美元($)。
我们纳入了 53 项研究;其中 45 项使用直接方法,8 项使用间接方法。直接方法的中位数估计值为每质量调整生命年(QALY)的 PPP$24942(范围为 554-1301912),通常为 0.53(范围为 0.02-24.08)人均 GDP。使用间接方法的中位数估计值为每 QALY 的 PPP$310051(范围为 36402-7574870),占 7.87(范围为 0.68-116.95)人均 GDP。
我们的综述发现,健康收益的社会价值或 CET 低于人均 GDP。方法和估计值的巨大差异表明,有必要为估计 CET 制定更标准化和国际认可的方法。当从社会角度来看,QALYs 不具有同等价值时(例如,接近死亡的人获得的 QALYs 与其他人的等效 QALYs 相比),可能需要多个 CET。